Back to News
Market Impact: 0.45
Rapport Therapeutics' RAP-219 Hits Phase II Goals in Bipolar Mania Trial
Source: marketbeat.com
Healthcare & BiotechCompany Fundamentals
Rapport Therapeutics reported positive top-line Phase II proof-of-concept results for RAP-219 in adults with acute bipolar mania, meeting both primary and secondary endpoints. The results support plans to advance the candidate into Phase III; the article provided no effect-size or safety details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.65
Ticker Sentiment
RAPP0.85
More News
- SpaceX closes $40 billion debt deal for AI chips, Elon Musk says
- Earnings playbook: Alphabet, Microsoft, Amazon and more report this week. Here's what to expect
- More pain may be coming for the AI trade. Why I’m not giving up on it
- AI Spending Fears Threaten to Swamp Big Tech’s Strong Earnings
- Apple to Unveil Touch-Screen MacBook Pro; Executive Promotions; In-Box Checker
- Musk Says SpaceX Closed $40 Billion Debt Deal, Blasts Neoclouds